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ABSTRACT 
Objective: Antibiotic resistance is a common complication in long-term urinary tract infections (UTIs). Alternative treatments, 
such as UroShield acoustic wave technology prevents bacteria from attaching to the surface of catheters and has reduced the 
number of treated UTIs. The objective of the study was to compare quantitative and qualitative outcomes in patients with 
long-term UTIs at the start of UroShield treatment and after a 12-week trial. 
Methods: 23 patients with reoccurring UTIs were offered to use UroShield for a period of 12 weeks. Objective and subjective 
measures of improvement were recorded every week, including the number of UTIs, antibiotic treatment, catheter blockage 
and changes, bladder washout, hospitalisations or nurse visits due to UTIs, level of pain, sleep, and mobility. The patients’ 
qualitative reports about the device were recorded. The ongoing study started in 2018. 
Results: Wilcoxon signed ranks non-parametric test and thematic analysis were used to detect changes in UTIs and self-
reported measures of pain and ease of wear. Patients reported a significant decrease in the number of UTIs and antibiotic 
treatment after a 12-week use of the Uroshield device (p < .001 and p = .009, respectively). Similarly, they had fewer catheter 
blockages and catheter changes (p = .006 and p < .001, respectively). Bladder washouts did not decrease over time. The pain 
was mild to moderate at the start of the trial which reduced significantly by the end of the trial (p = .017). Qualitative analysis 
confirmed the impact of the device on patients’ well-being, but an expanded study is needed to confirm these results. Further 
improvements to the device hardware have been identified by the patients. 
Conclusions: UroShield reduced the number of UTIs, catheter blockages and changes, and consequently the need for 
antibiotics. Patients reported the device is easy to use, were related to little to no pain, and overall improved patients’ well-being 
and mobility. We suggest the device should be considered as an appropriate treatment in long-term persistent UTIs. 
Keywords: Antibiotics; Antimicrobial resistance blockages; Catheter changes; Effectiveness; Pain; Preventative healthcare; 
Thematic analysis; Urinary tract infections; Uroshield 
INTRODUCTION 
A total of 150 million people worldwide are affected by urinary 
tract infections (UTIs) making it one of the most common 
bacterial infections [1]. UTIs are more common in women than 
in men: almost 50% of women will experience at least one UTI 
in their life while 33% of women will receive antibiotic treatment 
for a UTI before the age of 24 [2,3]. A prior UTI, sexual activity, 
vaginal infection, diabetes, obesity and genetic susceptibility have 
also been identified as significant risk factors [4,5]. 
UTIs can be categorized as uncomplicated or complicated [6]. 
Uncomplicated UTIs typically affect healthy individuals that 
are not afflicted by structural or neurological urinary tract issues 
[7,8]. Complicated UTIs occur when the urinary tract or host 
defence are compromised, and are commonly associated with
urinary obstruction, urinary retention caused by neurological 
disease, immunosuppression, renal failure, renal transplantation, 
pregnancy and the presence of foreign bodies such as calculi, 
indwelling catheters or other drainage devices [9,10]. 
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Historically, antibiotics such as trimethoprim sulfamethoxazole, 
ciprofloxacin and ampicillin have been common treatment options 
for uncomplicated and complicated UTIs 4. However, prophylactic 
antibiotic use is no longer the best course of action as it has been
shown to contribute to the development of antibiotic resistant 
mechanisms [11-13]. 
Different home remedies have been used to treat and prevent 
catheter associated UTI (CAUTI), such as the consumption 
of cranberry products [7,14], methenamine salts [7,15], and a 
sublingual bacterial vaccine [16,17]. However, most studies on the 
effectiveness of home remedies are inconclusive or insufficient at 
best [7,18]. 
UroShield (NanoVibronix) is a disposable ultrasound device 
designed to reduce the risk of CAUTI through the reduction
of bacterial colonization and biofilm formation on indwelling 
urinary catheters. It uses surface acoustic wave technology to 
prevent bacteria attaching to the surface of catheters, which
reduces antibiotic resistance and the patient's dose or shortening 
their treatment course [19]. UroShield was shown to be effective 
in significantly reducing the number of colony-forming units 
(CFUs) in patients with indwelling catheters as well as reducing 
the number of treated UTIs [20-23]. There was also a decrease in 
catheter-related pain scores in the UroShield group while they 
increased in the control group [24]. 
Further replications are needed to establish the effectiveness of 
UroShield, not just about reducing UTIs, but also its impact on
associated issues, such as catheter changes and blockages. The ease 
of use and patients’ feedback has not been recorded to the authors’ 
knowledge and we therefore strived to accompany quantitative 
measures with qualitative data from the patients’ experience. 
MATERIALS AND METHODS 
Patients 
Ideal Medical Solutions (IMS) approached a range of NHS trusts 
across the UK to offer them FOC (free of charge) evaluations 
of the UroShield Device. This was based across both primary 
and secondary care and any of the trusts willing to engage with
the evaluation were provided with the devices and monthly 
consumables for their ‘worst affected patients’. In the end we 
had engagement from the following trusts: Frimley Park Hospital, 
Broomfield Hospital, Northampton Community Team; Worcester 
Community Team, St. James’s Hospital and Pinderfields Hospital 
Spinal Injury Unit. 
Data collection took place between 2018 and 2020, and 23 of 
the patients are still utilising and benefitting from the UroShield 
device. 
The clinical teams at each site identified adult patients with repeated
UTI with a frequency of 2 or more UTIs in the last 6 months 
or 3 more UTIs in the last 12 months (European Association of 
Urology, 2017) and where they had exhausted all other avenues. 
At the beginning of each evaluation, consent was sought from all 
participants and NHS trusts included within this study. 
29 patients were originally recruited for the study, yielding a power 
of 84%. This was reduced to 73% by the end of the study with a 
total complete data set from 23 participants. During the evaluation, 
2 patients passed away from other healthcare complications and
four others withdrew for various medical reasons. Most patients 
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were on a trial for a period of 12 weeks, with a range between 5-17 
weeks. 
UroShield 
The UroShield device is designed to prevent bacterial biofilm 
formation on both urethral and suprapubic catheters through
the delivery of low frequency/low intensity ultrasound Surface 
Acoustic Waves (SAW). The ultrasound waves cannot be heard 
by the user; however, it prevents bacteria from being able to stick 
to the surface, and thus prevents the formation of biofilm. The 
device itself comprises of a driver element and a small disposable 
actuator clip which is replaced every 30 days. The driver element 
produces the ultrasound waves, and the actuator delivers them as it 
attaches to either the urethral or suprapubic catheter. It is designed
to be worn consistently to prevent the build-up of bacteria and is 
considered a preventative tool. 
Design and self-reported measures 
The baseline and end of trial surveys took information about the 
frequency of wear, and reasons when the device was turned off. It 
asked the patients about the number of urine infections in the past 
30 days, use of antibiotics, catheter changes, blockages and bladder 
washouts. It enquired about the need to see a GP, nurse or stay 
in a hospital due to UTIs related problems. Finally, the patients 
reported on their catheter related pain, quality of sleep, the ease 
of Uroshield wear and general mental health. The patients were 
encouraged to voice any comments related to the device. 
Statistical analysis 
The primary outcomes were UTIs and issues related to them. 
Secondary outcomes were qualitative data from the patients’ 
experience. Presence of symptoms was recorded on a continuous 
scale; the level of pain was measured on a 10-point Likert scale. 
Associations between baseline and end of study responses were 
examined using Wilcoxon signed ranks non-parametric test (SPSS
v.14.0; IBM Corp., Armonk, NY, USA). Thematic analysis was 
used to uncover themes related to the device wear 24, in order 
to understand patients’ experience better and provide better care 
in the future.  All statistical tests were two-tailed, and significance 
defined as p<.05. 
RESULTS 
Patients 
Most patient wore Uroshield 93% of the time (SD = 8.60), with no
patient wearing it less than 67% of the time. Most disconnections 
happened accidentally at night, commonly due to flat battery. 80% 
of patients were taking antibiotics while testing the device (some 
were on long-term Nitrofurantoin 100mg). 
Changes over time 
Data was not normally distributed, and Wilcoxon signed ranks 
non-parametric test was used to detect significant changes between
the baseline and the average mean results of the last month of the 
trial (Table 1). 
Patients reported significant decrease in the number of UTIs and
antibiotic treatment. Similarly, the patients had fewer catheter 
blockages and catheter changes. Bladder washouts did not decrease 
over time. Pain was mild to moderate at the start of the trial which
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Table 1: Descriptive statistics and Wilcoxon test for UroShield parameters over time. 
Variables N Mean SD Z p-value 
UTI, baseline 21 3.24 3.42 -3.179 .001*
 UTI, end 22 .50 .91
 Antibiotics, baseline 22 2.05 2.33 -2.614 .009*
 Antibiotics, end 22 .77 1.11 
Blockage, baseline 22 2.59 3.75 -2.755 .006* 
Blockage, end 22 .36 .90 
Change, baseline 22 2.91 3.57 -3.310 .001* 
Change, end 22 .32 .48 
Bladder, baseline 17 2.71 6.01 -1.625 .104 
Bladder, end 17 .65 1.69 
Pain, baseline 21 3.30 2.23 -2.395 .017* 
Pain, end 20 2.60 1.86 
*p < 0.05 
reduced significantly by the end of the trial. 
While most patients (N=16) did not report any improvement in 
their sleep patterns, 50% reported they felt happier about their 
urinary catheter (no one reported feeling worse). Similarly, 9 
patients (41%) reported they were able to do more things in their 
life due to using UroShield (four did not report changes; the rest of 
the data was missing). All patients who responded said UroShield 
was simple and easy to use, they felt comfortable using UroShield 
and they thought the device has benefitted them. This data is 
further corroborated by the qualitative responses from the patients. 
Thematic analysis 
Thematic analysis revealed two themes, one relating to the positive 
outcomes and the other to the issues related to the device. Positive 
outcomes had two further sub-themes: change to wellbeing and
design of the device. The device issue had two subthemes: issues 
caused by the patients’ other conditions and minor inconveniences. 
Positive outcomes: Patients shared many positive comments about 
UroShield. They mainly related to changes in their life and overall 
wellbeing but also the design of the device. This theme has been
represented by the largest volume of comments from the patients. 
Change to wellbeing- UroShield was designed to reduce the risk 
of catheter–associated urinary tract infections by producing low 
frequency low intensity ultrasonic SAW throughout the catheter, 
which interferes with the attachment of bacteria. The analysis of 
the patients’ comments during the 12-week trial shows that the 
device fulfils its task competently. It prevents further UTIs, catheter 
blockages and sediment build up. 
‘This is now longest period I have had without getting an infection (for 
over 4 years).’ 
‘Huge success! In nearly 7 years, this is the first time able to go a month 
before needing catheter changes.’ 
‘Not be continuously catheterised (often in the middle of the night), is a 
big plus.’ 
‘The overall effect whist not being black and white immediately is the 
feeling of general improvement and the life of this particular catheter has 
been extended by at least one week on this occasion resulting in longer 
periods between changes.’ 
The changes to patients’ conditions resulted in a better overall 
wellbeing and quality of their life. For many patients it means 
becoming more social, less worried about their conditions, and
becoming more independent: 
‘So happy I have got the UroShield again. Since the first trial finished and 
I no longer had the device my catheter was constantly blocking. Having the 
UroShield has changed my life!’ 
‘I haven't felt this good in years. It is lifechanging. Whoever thought of it 
deserves a medal.’ 
‘It gives me more confidence and freedom feeling I am unlikely to need a 
nurse due to catheter issues.’ 
Design of the device: The patients had mostly positive comments 
regarding the design of UroShield. Its instructions were written
clearly and were easy to follow by patients. It was reported the 
device was easy to get used to because of its conveniently small size 
and unrecognisable work: 
‘It was well explained to me […] and the handbook was very straight 
forward.’ 
‘Like anything new, once I got used to using it there was nothing to get 
uncomfortable about.’ 
‘The driver unit fits into a pocket.’ 
Device issues: Some patients reported issues during the UroShield 
trial. Most of these have been caused by comorbid conditions. The 
build-ups in the catheters occurred during the trial but UroShield 
was successfully preventing blockages, which was a positive 
outcome. 
Caused by patients' other conditions- Some patients had comorbid 
conditions, which negatively impacted the overall outcome of the 
treatment. Because of those some patients had a UTI during the 
trial or the device had to be taken off. Some patients were suffering 
from UTIs just before or during the first weeks of using the device. 
In that case UroShield did not help, and it is stated that UroShield 
is not supposed to be used to treat an active UTI. 
‘I have been unable to drink due to having dental problems which resulted 
in a UTI.’ 
‘In the beginning of the week my fluids were cut down because of a sickness 
bug.’ 
Minor inconveniences- The other group of discomfort during the 
UroShield trial were sediment build-ups, appearing in the catheter. 
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In those cases, the device was still successfully preventing blockages 
and catheter changes: 
‘Slight sediment build-up in the catheter but no blockage.’ 
‘The blockages were general build-up of rubbish that could be cleared by 
manipulation.’ 
‘Have had a lot of discomfort as a result of catheter. Also blood and blood 
clots noticed on 3 consecutive days when emptying leg bag.’ 
‘UroShield had to be removed for a couple of days as it caused irritation.’ 
Patients reported issues with the hardware malfunctions, most of 
which were battery related. The patients did not know the level of 
battery left: 
‘I wish there was more warning when battery was low on charge.’ 
‘I wish there was a second battery and that the unit shows when it is 
charging.’ 
‘I quickly realised that a powerpack would be beneficial. For under £20, 
the powerpack gives so much more freedom. I carry it always therefore never 
run out of power as the duration of the one supplied is restricting.’ 
‘It would be very useful if there was some way of knowing how much charge 
was left in the driver.’ 
‘The battery wasn't working properly, […], needed new device.’ 
‘Battery pack stopped working.’ 
Patients also reported some issues with the design of the device, 
especially the lead from the driver to the activator. It caused
problems with sleep and was uncomfortable during the day. Two 
patients mentioned that the clip device stopped working during 
the trial (although resetting it always helped) and that device 
should have its own holder which would be more comfortable in 
everyday use: 
‘The only negative point about the UroShield is that the charging 
lead is attached to the extension socket […]. If the Uroshield had its 
own holder that could be attached to the same holder that could be 
attached to the leg that would be great as it currently is put in the 
same holder as the catheter bag.’ 
‘Using the two leads when in bed is a nuisance. I now tape it to my leg.’ 
‘The extra lead from the driver to the catheter night bag is uncomfortable.’ 
‘Leads from the activator could have been longer.’ 
DISCUSSION 
The results showed that a 12-week UroShield wear in patients with
repeated UTIs significantly reduced the amount of UTIs. This is 
in line with previous studies where the device significantly reduced
the number of CFUs in patients with indwelling catheters as well 
as reducing the number of treated UTIs 20–23. Similarly, the need
for antibiotics decreased in the patient sample, and the number 
of catheter blockages and changes significantly reduced during the 
trial. 
The study additionally addressed the level of pain related to catheter 
pain, and while the level of reported pain was mild to moderate at 
baseline it reduced further by the end of the trial period, which is 
consistent with one previous study 19. 
All patients responded UroShield was simple and easy to use, they 
felt comfortable using it and they thought the device has benefitted
them. This data is further corroborated by the thematic analysis of 
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the qualitative responses from the patients, which revealed that the 
most common theme was the recognised positive outcomes about 
the changes to their lives as well as the convenience of the device. 
The patients reported a relief to be free from UTIs and pain, and
experienced increased freedom and independence in their day-to-
day life. 
While the device itself was mainly positively perceived by the 
patients, particularly about its small size and ease of use, some 
recognised the need to get used to the device, particularly about 
clearing the build-up and routinely charging the battery. These 
have been incorporated in the future instructions to the patients. 
CONCLUSION 
The first qualitative analysis of the UroShield patients has 
established a clearer picture about the usefulness of the device, 
which has been invaluable in understanding the patients’ lived 
experience. However, in the follow up study, the researchers have 
incorporated a standardized measure of quality of life to allow for 
a quantitative measure of the changes the device brings to patients’ 
quality of life. It will focuses on the effectiveness of UroShield on
suprapubic catheters as research in this area is limited. UroShield 
device should be considered as an effective treatment option for 
patients with repeated UTIs, as it not only reduces the number 
of UTIs, but also the need for antibiotics, the number of catheter 
changes and blockages, and catheter related pain. It is easy to use 
and discrete in its size, which results in improvement to patients’ 
wellbeing. 
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